Metabolic domino: New concept in lifestyle medicine

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A new concept has been proposed to capture the flow of events and chain reactions associated with cardiovascular risk: the metabolic domino. The metabolic domino differs for each individual based on their genetic predisposition. Lifestyle changes are the first dominoes to fall, which lead to obesity and insulin resistance, followed by post-prandial hyperglycemia, hypertension, and hyperlipidemia. Atherosclerosis then begins, and diabetes occurs once the domino for impairment of insulin secretion has toppled. Progression of the atherosclerotic process can lead to cardiovascular events such as ischemic heart diseases or cerebrovascular disorders. Preclinical and clinical data indicate that treatments which inhibit the renin angiotensin system, such as angiotensin receptor blockers, can suppress the onset of diabetes and, when administered even earlier in the metabolic domino, reduce the development of hypertension in at-risk individuals. The inhibition of inflammation with thiazolidinedione can also block the sequence of events leading to cardiovascular outcomes, as was shown with pioglitazone in the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive).

Original languageEnglish
Pages (from-to)9-16
Number of pages8
JournalDrugs of Today
Volume42
Issue numberSUPPL. C
Publication statusPublished - 2006 Dec

Fingerprint

pioglitazone
Life Style
Medicine
Hypertension
Cerebrovascular Disorders
Angiotensin Receptor Antagonists
Genetic Predisposition to Disease
Renin-Angiotensin System
Hyperlipidemias
Hyperglycemia
Myocardial Ischemia
Meals
Insulin Resistance
Atherosclerosis
Obesity
Clinical Trials
Insulin
Inflammation

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Metabolic domino : New concept in lifestyle medicine. / Itoh, Hiroshi.

In: Drugs of Today, Vol. 42, No. SUPPL. C, 12.2006, p. 9-16.

Research output: Contribution to journalArticle

@article{1afc1f8be05f4c6f997054fb4f9cdbae,
title = "Metabolic domino: New concept in lifestyle medicine",
abstract = "A new concept has been proposed to capture the flow of events and chain reactions associated with cardiovascular risk: the metabolic domino. The metabolic domino differs for each individual based on their genetic predisposition. Lifestyle changes are the first dominoes to fall, which lead to obesity and insulin resistance, followed by post-prandial hyperglycemia, hypertension, and hyperlipidemia. Atherosclerosis then begins, and diabetes occurs once the domino for impairment of insulin secretion has toppled. Progression of the atherosclerotic process can lead to cardiovascular events such as ischemic heart diseases or cerebrovascular disorders. Preclinical and clinical data indicate that treatments which inhibit the renin angiotensin system, such as angiotensin receptor blockers, can suppress the onset of diabetes and, when administered even earlier in the metabolic domino, reduce the development of hypertension in at-risk individuals. The inhibition of inflammation with thiazolidinedione can also block the sequence of events leading to cardiovascular outcomes, as was shown with pioglitazone in the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive).",
author = "Hiroshi Itoh",
year = "2006",
month = "12",
language = "English",
volume = "42",
pages = "9--16",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "SUPPL. C",

}

TY - JOUR

T1 - Metabolic domino

T2 - New concept in lifestyle medicine

AU - Itoh, Hiroshi

PY - 2006/12

Y1 - 2006/12

N2 - A new concept has been proposed to capture the flow of events and chain reactions associated with cardiovascular risk: the metabolic domino. The metabolic domino differs for each individual based on their genetic predisposition. Lifestyle changes are the first dominoes to fall, which lead to obesity and insulin resistance, followed by post-prandial hyperglycemia, hypertension, and hyperlipidemia. Atherosclerosis then begins, and diabetes occurs once the domino for impairment of insulin secretion has toppled. Progression of the atherosclerotic process can lead to cardiovascular events such as ischemic heart diseases or cerebrovascular disorders. Preclinical and clinical data indicate that treatments which inhibit the renin angiotensin system, such as angiotensin receptor blockers, can suppress the onset of diabetes and, when administered even earlier in the metabolic domino, reduce the development of hypertension in at-risk individuals. The inhibition of inflammation with thiazolidinedione can also block the sequence of events leading to cardiovascular outcomes, as was shown with pioglitazone in the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive).

AB - A new concept has been proposed to capture the flow of events and chain reactions associated with cardiovascular risk: the metabolic domino. The metabolic domino differs for each individual based on their genetic predisposition. Lifestyle changes are the first dominoes to fall, which lead to obesity and insulin resistance, followed by post-prandial hyperglycemia, hypertension, and hyperlipidemia. Atherosclerosis then begins, and diabetes occurs once the domino for impairment of insulin secretion has toppled. Progression of the atherosclerotic process can lead to cardiovascular events such as ischemic heart diseases or cerebrovascular disorders. Preclinical and clinical data indicate that treatments which inhibit the renin angiotensin system, such as angiotensin receptor blockers, can suppress the onset of diabetes and, when administered even earlier in the metabolic domino, reduce the development of hypertension in at-risk individuals. The inhibition of inflammation with thiazolidinedione can also block the sequence of events leading to cardiovascular outcomes, as was shown with pioglitazone in the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive).

UR - http://www.scopus.com/inward/record.url?scp=33846406957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846406957&partnerID=8YFLogxK

M3 - Article

C2 - 17245476

AN - SCOPUS:33846406957

VL - 42

SP - 9

EP - 16

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - SUPPL. C

ER -